Collegium Pharmaceutical (COLL) – Investment Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Collegium Pharmaceutical (NASDAQ: COLL) recently:

• 11/8/2025 – Collegium Pharmaceutical was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – Collegium Pharmaceutical had its price target raised by analysts at Truist Financial Corporation from $45.00 to $48.00. They now have a “buy” rating on the stock.
• 11/7/2025 – Collegium Pharmaceutical had its price target raised by analysts at HC Wainwright from $44.00 to $46.00. They now have a “buy” rating on the stock.
• 10/28/2025 – Collegium Pharmaceutical had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $46.00 price target on the stock.
• 10/23/2025 – Collegium Pharmaceutical was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 10/18/2025 – Collegium Pharmaceutical was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/8/2025 – Collegium Pharmaceutical had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Collegium Pharmaceutical had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 9/24/2025 – Collegium Pharmaceutical was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.

Insider Activity

In related news, EVP Scott Dreyer sold 16,389 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $38.21, for a total value of $626,223.69. Following the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at $3,959,052.73. This trade represents a 13.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas B. Smith sold 17,478 shares of Collegium Pharmaceutical stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $38.42, for a total transaction of $671,504.76. Following the completion of the sale, the executive vice president owned 70,264 shares in the company, valued at approximately $2,699,542.88. This represents a 19.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 69,272 shares of company stock worth $2,714,640 over the last ninety days. Insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.